Blood Cancer Journal
SCIE-ISI SCOPUS (2011-2023)
2044-5385
2044-5385
Mỹ
Cơ quản chủ quản: Springer Nature , Nature Publishing Group
Lĩnh vực:
OncologyHematology
Các bài báo tiêu biểu
CAR-T cell therapy: current limitations and potential strategiesAbstract Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effecti... ... hiện toàn bộ
Tập 11 Số 4
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blastsAbstract The adoptive transfer of CD19-specific chimeric antigen receptor engineered T cells (CAR T cells) resulted in encouraging clinical trials in indolent B-cell malignancies. However, they also show the limitations of this fascinating technology: CAR T cells can lead to even life-threatening off-tumor, on-target side effects if CAR T cells crossreact with healt... ... hiện toàn bộ
Tập 6 Số 8 - Trang e458-e458
IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphomaAbstract The biological role of monocytes and macrophages in B-cell non-Hodgkin lymphoma (NHL) is not fully understood. We have previously reported that monocytes from patients with B-cell NHL have an immunosuppressive CD14+ HLA-DRlow/− phenotype that correlates with a poor prognosis. However, the underlying mechanism by whic... ... hiện toàn bộ
Tập 5 Số 7 - Trang e328-e328
EZH2 alterations in follicular lymphoma: biological and clinical correlationsAbstract The histone methyltransferase EZH2 has an essential role in the development of follicular lymphoma (FL). Recurrent gain-of-function mutations inEZH2 have been described in 25% of FL patients and induce aberrant methylation of histone H3 lysine 27 (H3K27). We evaluated the role ofEZH2 genomic gains in FL bi... ... hiện toàn bộ
Tập 7 Số 4 - Trang e555-e555
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaAbstract Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet approximately 70% of AML are refractory to initial therapy or eventually relapse. This is at least partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that sustain the disease, and therefore novel anti-LSC therapies could decrease relapses and ... ... hiện toàn bộ
Tập 8 Số 6
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 casesAbstract We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous thrombosis (935/565), pooling three independent cohorts previously reported. Long-term treatment with antiplatelet drugs or vitamin K-antagonists (VKA) was given to 1391 (92.7%) patients; 975 (65%) patients received hydroxyurea (HU). We recorded 348 recurrences (venous... ... hiện toàn bộ
Tập 8 Số 11
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitorsAbstract The vast majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after standard induction chemotherapy. However, the majority subsequently relapse and die of the disease. A leukemia stem cell (LSC) paradigm has been invoked to explain this failure of CR to reliably translate into cure. Indeed, LSCs are highly enriched in CD34+... ... hiện toàn bộ
Tập 6 Số 9 - Trang e469-e469
Myelofibrosis Treatment Algorithm 2018Abstract Two novel prognostic systems for primary myelofibrosis (PMF) were recently unveiled: GIPSS (genetically inspired prognostic scoring system) and MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age patients). GIPSS is based exclusively on genetic markers: mutations and karyotype. MIPSS70 includes mutations and clinical risk f... ... hiện toàn bộ
Tập 8 Số 8